615
Participants
Start Date
December 31, 2004
Primary Completion Date
January 31, 2007
Study Completion Date
January 31, 2007
Placebo
Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
Aripiprazole
Tablets, oral, 15-30 mg, once daily, 12 weeks.
Haloperidol
Capsule, oral, 5-15 mg, once daily, 12 weeks.
Local Institution, Anaheim
Local Institution, Cerritos
Local Institution, Garden Grove
Local Institution, National City
Local Institution, Pico Rivera
Local Institution, Riverside
Local Institution, San Diego
Local Institution, Washington D.C.
Local Institution, Maitland
Local Institution, Tampa
Local Institution, Shreveport
Local Institution, Albuquerque
Local Institution, Cleveland
Local Institution, Oklahoma City
Local Institution, DeSoto
Local Institution, Burgas
Local Institution, Novi Iskar
Local Institution, Pleven
Local Institution, Sofia
Local Institution, Varna
Local Institution, Osijek
Local Institution, Rijeka
Local Institution, Split
Local Institution, Zagreb
Local Institution, Zapopan
Local Institution, Mexico City
Local Institution, Col. Obispado
Local Institution, Monterrey
Local Institution, Fracc. Industrias
Local Institution, Mérida
Local Institution, Nuevo León
Local Institution, Lima
Local Institution, Lipetsk
Local Institution, Arkhangelsk
Local Institution, Kazan'
Local Institution, Leningrad Region
Local Institution, Moscow
Local Institution, Nizhny Novgorod
Local Institution, Saint Petersburg
Local Institution, Samara
Local Institution, Volgograd
Local Institution, Florida
Local Institution, Pretoria
Local Institution, Berea
Local Institution, Durban
Collaborators (1)
Otsuka America Pharmaceutical
INDUSTRY
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY